Natera (NASDAQ:NTRA) Price Target Raised to $150.00 at Piper Sandler

Natera (NASDAQ:NTRA) had its price objective hoisted by Piper Sandler from $120.00 to $150.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

NTRA has been the subject of a number of other reports. The Goldman Sachs Group increased their target price on Natera from $90.00 to $100.00 and gave the stock a buy rating in a research note on Monday, April 15th. Stephens reissued an overweight rating and issued a $125.00 target price on shares of Natera in a report on Friday, August 9th. Canaccord Genuity Group upped their price target on shares of Natera from $100.00 to $130.00 and gave the stock a buy rating in a research note on Friday, May 10th. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a buy rating for the company in a research note on Friday, August 9th. Finally, BTIG Research upped their target price on shares of Natera from $125.00 to $135.00 and gave the stock a buy rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $119.07.

Natera Price Performance

Shares of NASDAQ NTRA opened at $123.98 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98. The company has a market cap of $15.23 billion, a PE ratio of -39.74 and a beta of 1.48. The stock has a fifty day moving average price of $108.72 and a 200 day moving average price of $96.45. Natera has a 1-year low of $36.90 and a 1-year high of $124.29.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business’s revenue was up 58.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.97) EPS. Sell-side analysts forecast that Natera will post -2.43 EPS for the current year.

Insiders Place Their Bets

In related news, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Steven Leonard Chapman sold 6,105 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $111.61, for a total transaction of $681,379.05. Following the sale, the chief executive officer now owns 213,351 shares in the company, valued at $23,812,105.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 96,308 shares of company stock valued at $10,580,675. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Several hedge funds have recently made changes to their positions in NTRA. Itau Unibanco Holding S.A. purchased a new position in Natera during the second quarter worth about $28,000. Quarry LP increased its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC raised its position in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. YHB Investment Advisors Inc. acquired a new stake in shares of Natera in the first quarter valued at about $36,000. Finally, Principal Securities Inc. purchased a new stake in shares of Natera during the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.